Department of Neurology

Department Home >

  • Base >
  • You are here
Department of Neurology
Increase Font Icon Increase Font Print Page Icon Print Page

Parkinson's Disease/Movement Disorders

  • Currently enrolling studies:

    1. 2 Care à study contact has changed to Lisa Altin, (215) 829-3582
    2. ANS DBS
      1. Primary study objective: To determine the efficacy of a new deep brain stimulator for the treatment of Parkinson’s disease
      2. Study population: Patients with Parkinson’s disease for at least 5 years
      3. Principal Investigator: Stacy Horn
      4. Study Contact: Mary Lloyd, RN , PhD, (215) 829-2365
    3. Cohort à study contact has changed to Lisa Altin. (215) 829-3582
    4. Droxidopa
      1. Primary study objective: To determine the safety and efficacy of droxidopa for the treatment of orthostatic hypotension.
      2. Study population: Patients with orthostatic hypotension (blood pressure drops after standing)
      3. Principal Investigator: Amy Colcher
      4. Study Contact: Mary Lloyd, RN, PhD, (215) 829-1265
    5. Mirapex à study contact is Mary Lloyd, RN, PhD, (215) 829-2365
    6. Net-PD
    7. Neurologix Gene therapy
      1. Primary study objective: To determine the efficacy of gene therapy for the treatment of Parkinson’s disease
      2. Study population: Patients with Parkinson’s disease
      3. Principal Investigator: Matthew Stern
      4. Study Contact: Heather Maccarone, RN, (215) 829-7181
    8. PARS
      1. Primary study objective: To determine why Parkinson’s disease develops through the study of relatives of patients with Parkinson’s disease
      2. Study population: First degree relatives of patients with Parkinson’s disease
      3. Principal Investigator: Matthew Stern
      4. Study Contact: Cybil Moural, (215) 829-7778 or  cybil.moural@uphs.upenn.edu
    9. QE3
      1. Primary study objective: To determine the efficacy of co-enzyme Q10 for the treatment of Parkinson’s disease
      2. Study population: Patients with Parkinson’s disease who are not taking Parkinson’s disease medications
      3. Principal Investigator: Andrew Siderowf
      4. Study Contact: Lisa Altin, (215) 829-3582
    10. Udall
      1. Primary study objective: To determine the natural history of cognition and memory in patients with Parkinson’s disease
      2. Study population: Patients with Parkinson’s disease who are older than 60 years of age
      3. Principal Investigators: Andrew Siderowf/ Howard Hurtig
      4. Study Contact: Emily Rosenthal, (215) 829-7104 or Katia Duey, (215) 829-7374
    11. AVID Florpiramine
      1. Primary study objective: To determine regional brain changes in patients with Parkinson’s disease through advanced neuroimaging.
      2. Study population: Patients with Parkinson’s disease who are older than 60 years of age
      3. Principal Investigator: Andrew Siderowf
      4. Study Contact: Cybil Moural, (215) 829-7778 or cybil.moural@uphs.upenn.edu